2026 年 3 月 25 日，开能健康科技集团股份有限公司（以下简称"公司"）全 资子公司开能健康细胞产业（海南）有限公司（以下简称"海南开能"）拟与关联 方原能细胞科技集团股份有限公司（以下简称"原能集团"）以及非关联方漳州九 龙江圆山集团有限公司（以下简称"九龙山圆山"）共同投资设立合资公司福建原 能细胞科技有限公司（以下简称"福建原能"或"合资公司"，暂定名以工商核定 为准），主要投资在漳州建设细胞存储库与制备实验室、细胞科普中心，及后续 的全自动细胞生产线等。合资公司注册资本为人民币 5,000 万元，其中，控股子 公司海南开能认缴出资人民币 600 万元，占注册资本的比例为 12%。 根据《深圳证券交易所创业板股票上市规则》相关规定，本次对外投资额度 及关联交易额度在公司在总经理审批权限范围内，无需提交董事会审议。本次交 易不构成《上市公司重大资产重组管理办法》规定的重大资产重组事项。 二、投资主体基本情况 1、关联方基本情况 证券代码：300272 证券简称：开能健康 公告编号：2026-004 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一 ...

证券代码：300272 证券简称：开能健康 公告编号：2026-003 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 开能健康科技集团股份有限公司（以下简称"公司"或"开能健康"）通过全 资子公司开能健康细胞产业（海南）有限公司（以下简称"海南开能细胞"）以现 金方式收购原能丽水持有的原天生物、丽水东昕 100%股权及原能集团持有的克勒 猫、基元美业 100%股权，交易价款为 20,381.66 万元。本次收购后，公司将持有原 天生物、基元美业、丽水东昕、克勒猫 100%股权，公司合并报表范围将新增以上 公司及其控股子公司（上海东昕、莱森原、欧珊尔）。 公司于 2025 年 11 月 21 日召开第六届董事会第二十九次会议、12 月 12 日召开 2025 年第三次临时股东会，审议通过了《关于公司全资子公司现金收购原能集团子 公司股权暨关联交易的议案》，并于 12 月 30 日完成了以上收购标的工商变更登记 手续。 具体内容请见公司在符合条件媒体披露的《关于公司全资子公司现金收购原能 集团部分子公司股权暨关联交易的公告》（公告编号：2025-095）、《关于 ...

Investment Rating - The report maintains a positive outlook on the home appliance sector, highlighting the potential for growth and stability in leading companies [4][5]. Core Insights - The report identifies two main investment themes: the value proposition of leading white and black appliance companies, which are characterized by low valuations, high dividends, and stable growth, and the technological advancements in the sector, with companies exploring new fields such as robotics and data centers [5][6]. - The report emphasizes the ongoing demand in emerging markets, which is expected to drive long-term growth for major appliance manufacturers [5][6]. Sales Data Summary - In January 2026, the online sales volume of vacuum cleaners reached 319,300 units, a year-on-year increase of 48.83%, with sales revenue of 352 million yuan, up 71.84%. The average price increased by 61.14% to 1,538.21 yuan per unit [4][33]. - The online sales volume of washing machines was 213,800 units, a year-on-year increase of 38.84%, with sales revenue of 243 million yuan, up 6.28%. The average price decreased by 25.43% to 1,106.95 yuan per unit [4][33]. - In contrast, the online sales of hair dryers and electric shavers saw declines, with hair dryer sales down 13.79% to 955,100 units and sales revenue down 8.38% to 225 million yuan. The average price increased by 22.96% to 272.1 yuan per unit [5][40]. Market Dynamics - The home appliance sector underperformed compared to the Shanghai and Shenzhen 300 index, with the home appliance index dropping 3.3% while the index fell 2.2% [6][7]. - The report notes a slight decline in the white goods market demand in early 2026, with air conditioning production and sales both down approximately 3.5% year-on-year [6][14]. Industry Developments - The successful launch of the "Yaotai" computing base station by Chasing Computing on March 16, 2026, marks a significant step towards establishing a space supercomputing center [6][13]. - The report highlights the ongoing adjustments in the export market due to international trade fluctuations, impacting the overall demand for home appliances [6][14]. Raw Material Price Trends - As of March 20, 2026, copper prices increased by 17.35% year-on-year to 95,820 yuan per ton, while aluminum prices rose by 15.67% to 24,065 yuan per ton [15][19].

Core Viewpoint - The article discusses the rising interest and regulatory challenges surrounding exosomes, a substance claimed to have anti-aging effects, which has not yet received approval for medical use in China [3][5]. Group 1: Regulatory Environment - The National Medical Products Administration in China has issued a draft for public consultation regarding the regulation of exosomes, which are still in the research phase and have not been approved for sale [3][5]. - There are concerns about the illegal use of exosomes in products, with some companies using improper certifications to market these substances, violating medical device regulations [5][6]. Group 2: Market Dynamics - Despite the lack of approved exosome products, companies like New Oxygen have previously launched related aesthetic medical products, although they have since been taken down [5]. - The consumer medical market is booming, prompting some CDMO manufacturers, originally focused on cell and gene therapy, to explore exosome-related businesses [6][7]. Group 3: Safety and Clinical Research - Experts warn about the safety of using exosomes in humans without proper regulatory approval, emphasizing the need for rigorous preclinical and clinical studies to validate safety and efficacy [7][8]. - Approximately 300 clinical trials related to exosomes are currently underway in China, with over 70 new studies registered in the past year, targeting various conditions such as sensitive skin diseases, arthritis, and hair loss [7].

证券代码：300272 证券简称：开能健康 公告编号：2026-002 （一）协议对方基本情况 1、名称：四川省医学科学院·四川省人民医院 2、法定代表人：傅启华 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、履约的重大风险及不确定性：在骨科、眼科及衰老相关疾病领域，开展多项 干细胞、免疫细胞制剂的 GCP 和 IIT 科研项目受科研项目的复杂性及多种因素影响， 存在不确定性。 2、根据科研合作项目进展及需求，项目周期预计五年，公司将按实际进度投入 设备及科研合作费用，分别计入长期资产和研发费用，不会对公司经营业绩产生重 大影响。 为积极响应国家关于促进生物医药创新与产业发展的政策导向，特别是依据《关 于支持医疗机构开展研究者发起的细胞治疗临床研究》等相关法规文件精神，开能 健康科技集团股份有限公司（以下简称"公司"或"开能健康"）决定由子公司上 海原天生物科技有限公司（以下简称"乙方"或"原天生物"）与四川省医学科学 院·四川省人民医院（以下简称"甲方"）签署《合作意向书》（以下简称"本协 议"或"合作协议"），在 2026 年至 2030 ...

Group 1 - The core viewpoint of the article is that Kaineng Health has responded to investor inquiries regarding its stake in Yuan Neng Bio, indicating that any disclosures related to the company will follow relevant regulations [2] Group 2 - Kaineng Health stated that Yuan Neng Bio is an associated enterprise, and for any disclosures involving the company, it will adhere to applicable rules [2] - Investors are advised to consult Yuan Neng Bio directly for specific details regarding the company [2]

Group 1 - The core point of the article is that Kaineng Health reported a total of 25,854 shareholders as of February 10, 2026 [2]

Group 1 - The core point of the article is that Kaineng Health (300272) reported a total of 25,728 shareholders as of January 30, 2026 [1]

Group 1 - The small home appliance sector experienced a decline of 1.22% on January 30, with Hongzhi Technology leading the drop [1] - The Shanghai Composite Index closed at 4117.95, down 0.96%, while the Shenzhen Component Index closed at 14205.89, down 0.66% [1] - Notable gainers in the small appliance sector included Fujia Co., which rose by 2.58% to a closing price of 18.68, and Rainbow Group, which increased by 1.92% to 23.33 [1] Group 2 - The small home appliance sector saw a net outflow of 123 million yuan from main funds, while retail investors contributed a net inflow of 105 million yuan [2] - Key stocks with significant fund flows included Feike Shiqi, which had a main fund net inflow of 8.34 million yuan, and Delmar, which saw a net inflow of 6.38 million yuan [3] - Conversely, Hongzhi Technology experienced a main fund net inflow of 739,500 yuan, but also had a significant retail net inflow of 610,200 yuan [3]

Market Overview - The small home appliance sector experienced a decline of 0.82% on January 27, with Kaineng Health leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Stock Performance - Notable gainers in the small home appliance sector included: - Jizhi Technology (code: 920926) with a closing price of 19.35, up 8.10% [1] - Liren Technology (code: 001259) with a closing price of 33.14, up 4.05% [1] - Beiyikang (code: 6610Z6) with a closing price of 44.00, up 2.11% [1] - Conversely, Kaineng Health (code: 300272) saw a significant decline of 3.34%, closing at 7.82 [2] Trading Volume and Capital Flow - The small home appliance sector saw a net outflow of 170 million yuan from institutional investors, while retail investors contributed a net inflow of 204 million yuan [2] - The trading volume for Jizhi Technology reached 60,800 shares, with a transaction value of 119 million yuan [1] Individual Stock Capital Flow - Key capital flow data for selected stocks: - Feike Shiqi (code: 603868) had a net inflow of 7.0385 million yuan from institutional investors, accounting for 10.52% of its trading [3] - Liren Technology (code: 001259) saw a net inflow of 5.1541 million yuan from institutional investors, representing 7.07% [3] - Beiyikang (code: 6610Z6) had a net inflow of 810,000 yuan from institutional investors, making up 0.82% [3]